Business Description
Celltrion is a South Korean biopharmaceutical company founded in 2002 and based in Incheon, specializing in the development and manufacture of biosimilar medicines that treat a wide range of serious conditions, including cancer, autoimmune diseases, and eye disorders. The company markets more than a dozen approved products across roughly 100 countries, with a strong presence in the United States and Europe. Celltrion also has several new treatments in late-stage clinical trials targeting conditions such as multiple myeloma, melanoma, multiple sclerosis, and hypertrophic cardiomyopathy.
